Bolt, US0977022039

Bolt Biotherapeutics stock reports a second-quarter loss

Published on 10/07/2026 at 06:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bolt Biotherapeutics stock was last at USD 3.51 on October 6, 2026, while second-quarter revenue reached USD 5,000. Diluted EPS was USD -4.57.

Bolt, US0977022039, Illustration mit AI erstellt.

Bolt Biotherapeutics (ISIN US0977022039) was last at USD 3.51 on Nasdaq on October 6, 2026 at 4:00 p.m. ET, up 0.31 percent from the prior close. The biotechnology company reported second-quarter revenue of USD 5,000 and diluted EPS of USD -4.57 for the period ended June 30, 2026, according to ToAlpha.

Q2 loss keeps the stock speculative

The second-quarter figures show a company still operating at a development-stage scale. Bolt Biotherapeutics generated USD 5,000 in revenue while recording a net loss of USD 7.72 million, giving the period a negative net margin of 154,400 percent, based on the reported figures for Q2 2026.

Diluted EPS declined from USD -4.31 in the first quarter of 2026 to USD -4.57 in the second quarter, a change of USD -0.26 per share. The comparison matters because the company remains dependent on clinical progress rather than commercial sales to support its valuation.

Cash position remains central

Bolt Biotherapeutics held USD 12.86 million in cash at June 30, 2026, compared with USD 11.61 million at March 31, 2026. Operating cash flow was negative USD 6.54 million in the second quarter, according to the same Q2 2026 financial summary published by ToAlpha.

That cash profile makes clinical milestones and financing capacity important valuation variables. The latest reported quarter combined a higher cash balance with continued operating cash consumption, leaving the company with USD 40.34 million in total assets at June 30, 2026.

Insider filing adds a watchpoint

In a Form 4 filed on September 21, 2026, COO Grant Yonehiro reported sales of 13,176 shares across September 16 through September 18. According to StockTitan, the sales covered tax withholding obligations linked to restricted stock unit vesting, with weighted average prices of USD 3.7740, USD 3.3183 and USD 3.2364.

The filing gives investors a concrete counterpoint to the clinical story, although the stated purpose was tax withholding rather than a discretionary investment decision. The stock's 52-week range was USD 3.10 to USD 7.20 on October 6, 2026, placing the latest price USD 0.41 above the low and USD 3.69 below the high.

Bolt stock remains near its yearly low

Bolt Biotherapeutics had a market capitalization of USD 6.7 million and trading volume of 13,249 shares on October 6, 2026. The USD 3.51 price therefore leaves the company valued near the bottom of its 52-week range, while the Q2 revenue and cash-flow figures keep clinical execution at the center of the investment case.